JP2007503202A5 - - Google Patents

Download PDF

Info

Publication number
JP2007503202A5
JP2007503202A5 JP2006521193A JP2006521193A JP2007503202A5 JP 2007503202 A5 JP2007503202 A5 JP 2007503202A5 JP 2006521193 A JP2006521193 A JP 2006521193A JP 2006521193 A JP2006521193 A JP 2006521193A JP 2007503202 A5 JP2007503202 A5 JP 2007503202A5
Authority
JP
Japan
Prior art keywords
cytotoxic
maytansine
formula
conjugate according
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006521193A
Other languages
English (en)
Other versions
JP2007503202A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/023340 external-priority patent/WO2005009369A2/en
Publication of JP2007503202A publication Critical patent/JP2007503202A/ja
Publication of JP2007503202A5 publication Critical patent/JP2007503202A5/ja
Pending legal-status Critical Current

Links

Description

Claims (1)

  1. 細胞毒性物質が、式(II)のメイタンシンDM4:
    である、請求項34に記載の細胞毒性コンジュゲート。
JP2006521193A 2003-07-21 2004-07-21 Ca6抗原特異的な細胞毒性コンジュゲートおよびその使用方法 Pending JP2007503202A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48844703P 2003-07-21 2003-07-21
PCT/US2004/023340 WO2005009369A2 (en) 2003-07-21 2004-07-21 A ca6 antigen-specific cytotoxic conjugate and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010262151A Division JP5643619B2 (ja) 2003-07-21 2010-11-25 Ca6抗原特異的な細胞毒性コンジュゲートおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2007503202A JP2007503202A (ja) 2007-02-22
JP2007503202A5 true JP2007503202A5 (ja) 2009-03-12

Family

ID=34102763

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006521193A Pending JP2007503202A (ja) 2003-07-21 2004-07-21 Ca6抗原特異的な細胞毒性コンジュゲートおよびその使用方法
JP2010262151A Expired - Fee Related JP5643619B2 (ja) 2003-07-21 2010-11-25 Ca6抗原特異的な細胞毒性コンジュゲートおよびその使用方法
JP2014133794A Expired - Fee Related JP5997727B2 (ja) 2003-07-21 2014-06-30 Ca6抗原特異的な細胞毒性コンジュゲートおよびその使用方法
JP2015237469A Expired - Fee Related JP6144749B2 (ja) 2003-07-21 2015-12-04 Ca6抗原特異的な細胞毒性コンジュゲートおよびその使用方法
JP2017033672A Pending JP2017123857A (ja) 2003-07-21 2017-02-24 Ca6抗原特異的な細胞毒性コンジュゲートおよびその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010262151A Expired - Fee Related JP5643619B2 (ja) 2003-07-21 2010-11-25 Ca6抗原特異的な細胞毒性コンジュゲートおよびその使用方法
JP2014133794A Expired - Fee Related JP5997727B2 (ja) 2003-07-21 2014-06-30 Ca6抗原特異的な細胞毒性コンジュゲートおよびその使用方法
JP2015237469A Expired - Fee Related JP6144749B2 (ja) 2003-07-21 2015-12-04 Ca6抗原特異的な細胞毒性コンジュゲートおよびその使用方法
JP2017033672A Pending JP2017123857A (ja) 2003-07-21 2017-02-24 Ca6抗原特異的な細胞毒性コンジュゲートおよびその使用方法

Country Status (27)

Country Link
US (1) US20050123549A1 (ja)
EP (1) EP1660513B9 (ja)
JP (5) JP2007503202A (ja)
KR (5) KR101672664B1 (ja)
CN (3) CN1922199B (ja)
AT (1) ATE496944T1 (ja)
AU (1) AU2004258955C1 (ja)
BR (1) BRPI0412879A8 (ja)
CA (1) CA2532430C (ja)
CR (1) CR8207A (ja)
CY (1) CY1111938T1 (ja)
DE (1) DE602004031239D1 (ja)
DK (1) DK1660513T5 (ja)
EA (1) EA014640B1 (ja)
EC (1) ECSP066294A (ja)
ES (1) ES2360403T3 (ja)
HK (2) HK1098160A1 (ja)
HR (1) HRP20110302T1 (ja)
IL (2) IL172982A (ja)
MX (2) MXPA06000830A (ja)
NO (1) NO339324B1 (ja)
NZ (3) NZ580855A (ja)
PL (1) PL1660513T3 (ja)
PT (1) PT1660513E (ja)
SI (1) SI1660513T1 (ja)
WO (1) WO2005009369A2 (ja)
ZA (1) ZA200600375B (ja)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6596503B1 (en) 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US9539348B2 (en) 2000-08-18 2017-01-10 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
EP3851126A1 (en) * 2003-05-20 2021-07-21 ImmunoGen, Inc. Maytansinoid-cell-binding agent conjugates
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
CA2615761A1 (en) * 2005-08-22 2007-03-01 Immunogen, Inc. Humanized anti-ca6 antibodies and methods of using the same
CN104804094A (zh) * 2005-08-22 2015-07-29 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
CA2710483C (en) * 2007-12-26 2018-05-08 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells
CN101952315B (zh) * 2007-12-26 2015-04-01 生物测试股份公司 靶向cd138的试剂及其应用
EP2238169A1 (en) * 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
DK2242772T3 (en) * 2007-12-26 2015-01-05 Biotest Ag Immunoconjugates that targets CD138, and uses thereof
KR20230003298A (ko) 2008-04-30 2023-01-05 이뮤노젠 아이엔씨 가교제 및 그 용도
KR101725170B1 (ko) * 2009-05-06 2017-04-10 바이오테스트 아게 Cd138을 표적으로 하는 면역접합체의 용도
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
AU2011215900A1 (en) 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
AU2012205301B2 (en) * 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
CN103826661B (zh) 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途
JP2014530201A (ja) * 2011-09-20 2014-11-17 イーライ リリー アンド カンパニー 抗c−Met抗体
RU2632108C2 (ru) 2011-12-08 2017-10-02 Биотест Аг Применения иммуноконъюгатов, мишенью которых является cd138
JP2012161321A (ja) * 2012-03-30 2012-08-30 Immunogen Inc Ca6抗原特異的細胞傷害性コンジュゲート、および該コンジュゲートを用いる方法
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US9989524B2 (en) 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US9844607B2 (en) 2013-02-05 2017-12-19 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
CA2900154A1 (en) 2013-02-05 2014-08-14 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
ES2859398T3 (es) 2013-03-15 2021-10-01 Beckman Coulter Inc Métodos para diseño de panel en citometría de flujo
JP2016525560A (ja) * 2013-08-02 2016-08-25 サノフイ 固形腫瘍を処置するための抗−Muc1メイタンシノイドイムノコンジュゲート抗体の使用
ES2815098T3 (es) 2013-12-23 2021-03-29 Bayer Pharma AG Conjugados de ligadores (ADCs) con inhibidores de KSP
MX2016011627A (es) * 2014-03-12 2016-11-29 Novartis Ag Sitios especificos para modificar anticuerpos con el fin de hacer inmunoconjugados.
WO2016036861A1 (en) 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
TWI697493B (zh) 2014-09-03 2020-07-01 美商免疫原公司 細胞毒性苯并二氮呯衍生物
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
CN114917361A (zh) 2015-06-22 2022-08-19 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物(adc)和抗体前药缀合物(apdc)
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
RS65120B1 (sr) 2015-11-25 2024-02-29 Immunogen Inc Farmaceutske formulacije i postupci za njihovu upotrebu
KR20180123047A (ko) 2016-03-24 2018-11-14 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
PE20191235A1 (es) 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
CN110312533B (zh) 2016-12-21 2023-11-03 拜耳公司 具有酶促可裂解的基团的细胞毒性活性剂的前药
CN116785450A (zh) 2017-02-28 2023-09-22 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
TW201839001A (zh) 2017-04-20 2018-11-01 美商伊繆諾金公司 細胞毒性苯并二氮平衍生物及其綴合物
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019133652A1 (en) 2017-12-28 2019-07-04 Immunogen, Inc. Benzodiazepine derivatives
CA3133155A1 (en) 2019-03-19 2020-09-24 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron Combination therapy for the treatment for cancer
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2023150677A2 (en) * 2022-02-03 2023-08-10 Igm Biosciences, Inc. Anti-cd38 binding molecules and uses thereof
WO2024089013A1 (en) 2022-10-25 2024-05-02 Peptomyc, S.L. Combination therapy for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK0605522T3 (da) * 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0752248B1 (en) * 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US20030143233A1 (en) * 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
ATE349438T1 (de) * 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
US6596503B1 (en) * 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CA2462790A1 (en) * 2001-10-04 2003-04-10 Immunex Corporation Ul16 binding protein 4
CA2467242A1 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
KR20080106369A (ko) * 2002-01-02 2008-12-04 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
CN102940889A (zh) * 2003-05-14 2013-02-27 伊缪诺金公司 药物缀合物组合物

Similar Documents

Publication Publication Date Title
JP2007503202A5 (ja)
JP2006526031A5 (ja)
JP2006515626A5 (ja)
JP2005522505A5 (ja)
JP2010501534A5 (ja)
JP2007522220A5 (ja)
JP2003503454A5 (ja)
JP2006240292A5 (ja)
JP2004536811A5 (ja)
JP2006503588A5 (ja)
JP2002332234A5 (ja)
JP2009535462A5 (ja)
JP2008520662A5 (ja)
JP2005053931A5 (ja)
JP2009502793A5 (ja)
JP2007510619A5 (ja)
JP2008517059A5 (ja)
JP2008513510A5 (ja)
JP2008540542A5 (ja)
JP2010520214A5 (ja)
JP2009522364A5 (ja)
JP2010520851A5 (ja)
JP2007520206A5 (ja)
JP2008260517A5 (ja)
JP2003160581A5 (ja)